Geode Capital Management LLC Acquires 23,443 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geode Capital Management LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 542,523 shares of the medical instruments supplier's stock after buying an additional 23,443 shares during the period. Geode Capital Management LLC owned 2.41% of LeMaitre Vascular worth $50,403,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock worth $183,769,000 after acquiring an additional 36,850 shares in the last quarter. Copeland Capital Management LLC raised its position in LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier's stock valued at $108,068,000 after purchasing an additional 11,318 shares during the last quarter. State Street Corp boosted its stake in LeMaitre Vascular by 3.6% in the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock worth $76,363,000 after purchasing an additional 28,525 shares in the last quarter. Congress Asset Management Co. grew its holdings in shares of LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier's stock worth $65,888,000 after purchasing an additional 18,295 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LMAT. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Oppenheimer reissued an "outperform" rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research boosted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus price target of $94.57.

Insider Activity at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

LMAT traded down $0.74 during trading on Monday, reaching $91.38. 131,356 shares of the company's stock were exchanged, compared to its average volume of 131,708. The company's fifty day moving average price is $97.74 and its 200-day moving average price is $90.16. The firm has a market capitalization of $2.05 billion, a PE ratio of 49.93, a P/E/G ratio of 2.47 and a beta of 0.93. LeMaitre Vascular, Inc. has a fifty-two week low of $52.88 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. The firm's revenue was up 15.6% on a year-over-year basis. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.70%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular's payout ratio is 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.